Berkeley Scientists Find Fat-Burning Compound Called TOFA

Scientists at UC Berkeley just found a promising new approach to fighting obesity that doesn't rely on eating less.

The research team identified a compound called TOFA that helps the body burn more energy rather than suppressing appetite like current weight loss medications. In studies with mice, the molecule improved fat burning, blood sugar control, and liver health without significant muscle loss.

TOFA works through a dual action that sets it apart from existing treatments. It blocks the production of fats like cholesterol while simultaneously activating genes that help cells burn fat for energy. This combination increased energy expenditure in mice by up to 18% without changing how much they ate or exercised.

The discovery addresses a major concern with popular GLP-1 drugs like Ozempic and Wegovy. While those medications have transformed obesity treatment, they can cause nausea and gastrointestinal problems. Because they work by reducing appetite, they may also lead to nutritional deficiencies and muscle loss.

"Body weight responds to two levers: taking in fewer calories, or spending more energy," said Anders Näär, professor of metabolic biology at UC Berkeley. "GLP-1s work almost entirely on the first, so we went after the second."

TOFA also avoided a problem that derailed similar compounds in the past. Many drugs that block fat production unfortunately raise triglyceride levels, potentially increasing heart disease risk. TOFA's dual mechanism appears to prevent this issue.

Why This Inspires

The Berkeley team tested TOFA alongside existing GLP-1 medications and found something remarkable. The combination produced better results for weight loss, blood sugar, and triglyceride levels than either treatment alone. This suggests TOFA could enhance current therapies rather than replace them.

Obese mice treated with TOFA lost fat while maintaining lean muscle mass. They also showed improved insulin sensitivity and reduced features of fatty liver disease. The compound appeared to create a coordinated metabolic response that helped the body handle excess fat and sugar more effectively.

The researchers tried reproducing TOFA's effects by giving mice separate compounds to block fat production and increase energy use. That combination didn't work as well as TOFA alone, suggesting the molecule's unique structure matters.

TOFA was actually discovered in the 1970s but is only now being explored for metabolic disease. The Berkeley team has founded a company called ReRx Therapeutics to develop the approach further.

Scientists caution that TOFA has only been studied in animals so far, and its safety and effectiveness in people remain unknown. Human trials will be needed to determine whether this promising mouse research translates to real treatments.

The research offers hope for expanding the toolkit against obesity and diabetes beyond appetite suppression alone.